Clinical Updates
Safety and Efficacy of Delpacibart Zotadirsen in Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping: Insights from the EXPLORE44 Phase 1/2 Trial
Delpacibart zotadirsen demonstrates an acceptable safety profile and significant increases in exon 44 skipping and dystrophin expression in DMD patients amenable to exon 44 skipping, supporting further phase 3 evaluation.
